These findings are noteworthy, because we recently showed that MEF2c gain‐of‐function protects against cancer‐associated muscle wasting and weakness,68 and highlight FoxP1 up‐regulation as a novel mechanism that contributes to the disruption of MEF2 target gene transcription during cancer cachexia. The gene discussed is FOXP1; the disease is cancer.